Feb 20, 2019 / 01:00PM GMT
Operator
Ladies and gentlemen, welcome to the Sobi presentation of the Q4 results. I will now hand you over to Guido Oelkers, CEO.
Guido Oelkers - Swedish Orphan Biovitrum AB(publ)-CEO&President
Yes. Thank you so much. This is Guido. I'm joined today by Milan Zdravkovic, Head of R&D; and by Henrik Stenqvist, our CFO. It's really a great pleasure to share with you the results, and I think I would like to go straight into the meat of the presentation to give time for Q&A.
You've seen our results. Total revenues for the year now increased 40% and 74% on the earnings. In Q4, we had a nice increase as well. We are with SEK 2.571 billion revenues and which represents a 37% increase and an EBITDA of SEK 916 million for the total year at SEK 3.571 million. So when you look at these earnings per shares increased as a consequence as well to SEK 8.97 and the whole thing was quite cash accretive so we were able to build in a year of investment also our net cash position.
I think very important to us is
Q4 2018 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Feb 20, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers